12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Cylene Pharmaceuticals preclinical data

In a mouse model of lymphoma, a single oral dose CX-5461 significantly reduced tumor burden in lymph nodes (p<0.01) and significantly reduced...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >